MRNS — Marinus Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $78.56m
- $38.78m
- $30.99m
- 37
- 11
- 17
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -142.02% | ||
| Return on Equity | -423.43% | ||
| Operating Margin | -474.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 1.72 | 15.35 | 25.48 | 30.99 | 39.34 | 58.17 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
Directors
- Nicole Vitullo NEC (63)
- Scott Braunstein PRE
- Steven Pfanstiel CFO (49)
- Martha Manning VPR (66)
- Joseph Hulihan OTH (65)
- Santiago Arroyo DRC
- Charles Austin IND (65)
- Michael Dougherty IND (63)
- Elan Ezickson IND (57)
- Seth Fischer IND (65)
- Timothy Mayleben IND (61)
- Saraswathy Nochur IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- August 14th, 2003
- Public Since
- July 31st, 2014
- No. of Shareholders
- 11
- No. of Employees
- 165
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 54,933,774
- Address
- Three Radnor Corporate Center, RADNOR, 19087
- Web
- https://marinuspharma.com/
- Phone
- +1 4848014670
- Contact
- Sasha Ellis
- Auditors
- Ernst & Young LLP
Upcoming Events for MRNS
Q3 2024 Marinus Pharmaceuticals Inc Earnings Release
Similar to MRNS
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
Alimera Sciences
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
FAQ
What is the Marinus Pharmaceuticals share price?
As of Today at 15:58 UTC, shares in Marinus Pharmaceuticals are trading at $1.33. This share price information is delayed by 15 minutes.
How has the Marinus Pharmaceuticals share price performed this year?
Shares in Marinus Pharmaceuticals last closed at $1.33 and the price had moved by -87.44% over the past 365 days. In terms of relative price strength the Marinus Pharmaceuticals share price has underperformed the S&P500 Index by -90.01% over the past year.
What are the analyst and broker recommendations for Marinus Pharmaceuticals?
The overall consensus recommendation for Marinus Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Marinus Pharmaceuticals dividend yield?
Marinus Pharmaceuticals does not currently pay a dividend.
Does Marinus Pharmaceuticals pay a dividend?
Marinus Pharmaceuticals does not currently pay a dividend.
When does Marinus Pharmaceuticals next pay dividends?
Marinus Pharmaceuticals does not currently pay a dividend.
How do I buy Marinus Pharmaceuticals shares?
To buy shares in Marinus Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Marinus Pharmaceuticals?
As of the previous close price of $1.33, shares in Marinus Pharmaceuticals had a market capitalisation of $73.06m.
Where are Marinus Pharmaceuticals shares listed?
Here are the trading details for Marinus Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: MRNS
What kind of share is Marinus Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Marinus Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Marinus Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Marinus Pharmaceuticals is $6.90. That is 418.8% above the last closing price of $1.33.
Analysts covering Marinus Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.96 for the next financial year.
What is the trend in the Marinus Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Marinus Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -88.87%.
As of the last closing price of $1.33, shares in Marinus Pharmaceuticals were trading -80.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Marinus Pharmaceuticals PE Ratio?
The Marinus Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Marinus Pharmaceuticals?
Marinus Pharmaceuticals' management team is headed by:
- Nicole Vitullo - NEC
- Scott Braunstein - PRE
- Steven Pfanstiel - CFO
- Martha Manning - VPR
- Joseph Hulihan - OTH
- Santiago Arroyo - DRC
- Charles Austin - IND
- Michael Dougherty - IND
- Elan Ezickson - IND
- Seth Fischer - IND
- Timothy Mayleben - IND
- Saraswathy Nochur - IND